Heads of HTA Agencies Group convene in Lisbon for fourth meeting

By Staff Writer

January 18, 2023

HTA Agencies Meeting Updates: It seems the Heads of HTA Agencies Group had a productive meeting in Lisbon, Portugal. They discussed key strategic topics including the confirmation of the new Vice-Chair, updates on the HTA Regulation and long-term strategic planning for the group!

Next meeting will take place in Stockholm, Sweden in May 2023.

Reference url

Recent Posts

EU AI Act Healthcare Compliance
     

Navigating EU AI Act Healthcare Compliance: Proactive Steps for Ethical AI Integration

🔍 Are you prepared for the upcoming EU AI Act in healthcare?

As the first comprehensive AI regulation globally rolls out, healthcare organizations must move beyond mere compliance. The urgency lies in embedding ethical, trusted, and sustainable AI practices into every facet of healthcare AI. Early adoption of ethical assessments and collaboration is essential to navigate the complex regulatory landscape before the August 2026 deadline.

Learn about proactive compliance strategies that not only meet regulatory standards but also enhance patient trust and system efficacy!

#SyenzaNews #AIinHealthcare #HealthcareInnovation #DigitalTransformation

hepatitis vaccine uptake
         

Hepatitis Vaccine Uptake: Trends, Challenges, and the Role of Pharmacists

💉 Are we doing enough to bridge the gap in hepatitis vaccine uptake?

A recent article highlights that while over 90% of children are vaccinated against hepatitis B, adult rates are alarmingly low, posing a significant public health risk. Jeff Goad from the National Foundation for Infectious Diseases emphasizes the crucial role pharmacists can play in increasing access and dispelling common misconceptions about vaccines.

Join the conversation on enhancing vaccination strategies for better health outcomes!

#SyenzaNews #Healthcare #HealthEconomics

biosimilars price competition
            

Biosimilars Price Competition: Impact on U.S. Pharmaceutical Pricing and Market Sustainability

💡 Are biosimilars the key to transforming U.S. healthcare costs?

A recent study reveals that as more biosimilars enter the market, original product prices drop significantly—by as much as 10-13% per competitor! This shift has led to astonishing savings, totaling $23.6 billion for Medicare between 2015 and 2023. However, concerns linger about the long-term sustainability of this competitive pricing environment.

Dive into the insights on how this booming market balances immediate cost reductions with potential future challenges.

#SyenzaNews #HealthEconomics #Pharmaceuticals #HealthcarePolicy

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.